eloralintide tirzepatide will be the obesity drug of the future. It will likely be approved to combine with other GLP-1 therapies to achieve greater results. A phase 3 trial for this is already eloralintide vs retatrutide Triple Agonism

The pivotal trials tested 0.25mg as the lowest dose, and even that was considered a non-therapeutic escalation dose

Altmed can discuss candidacy, medication safety, visit costs, prescription considerations, and next steps so patients understand the financial and medical side before committing

Given the announcement of the $245 figure to be charged to public insurers in Medicaid and Medicare, is this then also the Medicares so-called maximum fair price negotiated for semaglutide-based productsOzempic, Rybelsus and Wegovyunder the Inflation Reduction Acts drug pricing provisions

18, 2024 from Durell, N., Franks, R., Coon, S., et al